Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus ELFABRIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus ELFABRIO.
ALDURAZYME vs ELFABRIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
0.58 mg/kg administered intravenously once weekly.
1 mg/kg intravenously over 2 hours every 2 weeks.
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy